Angiogenesis & Cancer Drug discovery group
Department of Life Sciences
European University Cyprus
Dr. Malamati Kourti is a Lecturer of Pharmacy at the Department of Life Sciences of the European University Cyprus (2019-today), where she teaches Molecular Pharmacology, Pharmacology, Biotechnology and Toxicology. She received her B.Sc. degree in Pharmacy in 2013 from the Aristotle University of Thessaloniki, Greece, receiving a rewarding scholarship from the Department of studies (2009) and a scholarship for Excellence from the Greek State Scholarships Foundation (2010). She received her M.Sc. degree in Pharmacy (with Honours, 2015) specialized in “Medicinal Chemistry, Development of pharmaceutical compounds” from the same university. Malamati then joined the laboratories of Prof. A. Westwell (School of Pharmacy & Pharmaceutical Sciences) and Dr. J. Cai (School of Medicine) at Cardiff University, UK, to pursue a Ph.D. in cancer research, as a Life Sciences Research Network Wales fellow (Ph.D. in Medicine/Pharmacy, 2019). Her research interests mainly focus on malignant angiogenesis and the interplay between oxidative stress and cancer. She is interested in unraveling the underlying mechanisms of angiogenesis, with the aim to identify novel anti-angiogenic drug targets, especially for breast cancer. She has previously worked with a group of organometallic complexes called carbon monoxide-releasing compounds (CORMs), which are currently explored as potential anti-cancer and anti-angiogenic agents. Moreover, the use of synthetic or natural prooxidant and antioxidant compounds as novel anti-cancer strategies is of interest. Her publications cover a range of Medicinal Chemistry and Cancer Biology topics in high impact factor journals (h-index=5; citations=99; source: Scopus. h-index=5; citations=108; source: Google Scholar). She is also a member of several professional bodies, including the European Association for Cancer Research. Malamati is currently leading the “Angiogenesis and Cancer Drug Discovery” group of the BTCRC.
Our research group mainly focuses on malignant angiogenesis and the interplay between oxidative stress or inflammation and cancer. In this scope, one of the interests of the group is to unravel the underlying mechanisms of angiogenesis, with the aim to identify novel anti-angiogenic drug targets, especially for breast cancer. Specific mention shall be made to carbon monoxide-releasing compounds (CORMs), which are a group of organometallic complexes currently explored as potential anti-cancer and anti-angiogenic agents, and are part of our research endeavors. Moreover, the use of synthetic or natural prooxidant and antioxidant compounds as novel anti-cancer strategies is of interest, as well as the potential use of anti-inflammatory drugs against inflammatory cancer subtypes. The findings will be considered under the scope of Medicinal Chemistry, where novel compounds will be identified or derivatives of existing agents will be synthesized and explored as potential anti-cancer approaches.
Current Group Members
Anna Maria Papanastasiou
Past Group Members
Life Sciences Research Network Wales (NRN509876, 01/10/2015 – 30/09/2018) and Cardiff University School of Medicine and School of Pharmacy & Pharmaceutical Sciences (internal funding)
Role: Project Coordinator